Deciphera Pharmaceuticals (NASDAQ:DCPH) Rating Reiterated by Guggenheim

Guggenheim reaffirmed their neutral rating on shares of Deciphera Pharmaceuticals (NASDAQ:DCPH) in a research report sent to investors on Tuesday, Benzinga reports.

Other analysts have also recently issued research reports about the company. Jonestrading restated a hold rating and set a $25.60 target price on shares of Deciphera Pharmaceuticals in a report on Monday, April 29th. Jefferies Financial Group reissued a hold rating and set a $25.60 price objective (down previously from $26.00) on shares of Deciphera Pharmaceuticals in a report on Monday, April 29th. Stifel Nicolaus boosted their target price on shares of Deciphera Pharmaceuticals from $22.00 to $23.00 and gave the stock a buy rating in a research note on Wednesday, February 7th. JMP Securities reissued a market perform rating on shares of Deciphera Pharmaceuticals in a research note on Tuesday. Finally, Barclays raised shares of Deciphera Pharmaceuticals from an underweight rating to an equal weight rating and raised their price target for the company from $9.00 to $26.00 in a report on Tuesday. Seven analysts have rated the stock with a hold rating and three have issued a buy rating to the company’s stock. According to data from MarketBeat, the company presently has an average rating of Hold and a consensus price target of $24.17.

Deciphera Pharmaceuticals Price Performance

Shares of DCPH stock opened at $25.38 on Tuesday. The company has a market capitalization of $2.09 billion, a P/E ratio of -11.08 and a beta of 0.20. Deciphera Pharmaceuticals has a 12-month low of $9.90 and a 12-month high of $25.47. The firm has a 50-day moving average price of $16.56 and a 200 day moving average price of $14.80.

Deciphera Pharmaceuticals (NASDAQ:DCPH) last posted its earnings results on Tuesday, February 6th. The company reported ($0.54) earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of ($0.58) by $0.04. The company had revenue of $48.30 million during the quarter, compared to analysts’ expectations of $45.93 million. Deciphera Pharmaceuticals had a negative net margin of 119.33% and a negative return on equity of 49.44%. Deciphera Pharmaceuticals’s quarterly revenue was up 32.9% compared to the same quarter last year. During the same quarter in the previous year, the company posted ($0.60) earnings per share. As a group, research analysts expect that Deciphera Pharmaceuticals will post -2.16 earnings per share for the current year.

Hedge Funds Weigh In On Deciphera Pharmaceuticals

A number of hedge funds and other institutional investors have recently bought and sold shares of the business. Deerfield Management Company L.P. Series C lifted its stake in shares of Deciphera Pharmaceuticals by 2.8% in the 3rd quarter. Deerfield Management Company L.P. Series C now owns 6,897,606 shares of the company’s stock valued at $87,738,000 after purchasing an additional 190,580 shares during the period. Deutsche Bank AG boosted its holdings in Deciphera Pharmaceuticals by 36.7% during the third quarter. Deutsche Bank AG now owns 254,671 shares of the company’s stock worth $3,239,000 after buying an additional 68,435 shares during the last quarter. Panagora Asset Management Inc. acquired a new position in shares of Deciphera Pharmaceuticals during the 3rd quarter worth about $1,167,000. Dark Forest Capital Management LP increased its stake in shares of Deciphera Pharmaceuticals by 18.9% in the 3rd quarter. Dark Forest Capital Management LP now owns 60,216 shares of the company’s stock valued at $766,000 after acquiring an additional 9,553 shares during the last quarter. Finally, Diversified Trust Co acquired a new stake in shares of Deciphera Pharmaceuticals in the 4th quarter valued at approximately $193,000. 70.96% of the stock is owned by institutional investors.

About Deciphera Pharmaceuticals

Deciphera Pharmaceuticals, Inc, a biopharmaceutical company, develops drugs to enhance the lives of cancer patients by addressing key mechanisms of drug resistance that limit the rate and durability of response to existing cancer therapies in the United States and internationally. Its lead drug candidate is QINLOCK used for the treatment of gastrointestinal stromal tumors (GIST), as well as in INTRIGUE Phase 3 study to treat second-line GIST.